| [1] |
MOELLERING R C.Tedizolid:a novel oxazolidinone for Gram-positive infections[J]. Clin Infect Dis,2014,58(Suppl 1):S1-S3.
|
| [2] |
ARIAS C A,MURRAY B E.The rise of the Enterococcus:beyond vancomycin resistance[J]. Nat Rev Microbiol,2012,10(4):266-278.
|
| [3] |
SONG J H.Advances in pneumococcal antibiotic resistance[J]. Expert Rev Respir Med,2013,7(5):491-498.
|
| [4] |
SONG J H,HSUEH P R,CHUNG D R,et al.Spread of methicillin-resistant Staphylococcus aureus between the community and the hospitals in Asian countries:an ANSORP study[J]. J Antimicrob Chemother, 2011,66(5):1061-1069.
|
| [5] |
TSAI H Y,LIAO C H,CHEN Y H,et al.Trends in susceptibility of vancomycin-resistant Enterococcus faecium to tigecycline,daptomycin,and linezolid and molecular epidemiology of the isolates:results from the tigecycline in vitro surveillance in Taiwan (TIST) study,2006 to 2010[J]. Antimicrob Agents Chemother,2012,56(6):3402-3405.
|
| [6] |
CHEN K H,HUANG Y T,LIAO C H,et al.In vitro activities of tedizolid and linezolid against Gram-positive cocci associated with acute bacterial skin and skin structure infections and pneumonia[J]. Antimicrob Agents Chemother,2015,59(10):6262-6265.
|
| [7] |
CROTTY M P,KREKEL T,BURNHAM C A,et al.New Gram-positive agents:the next generation of oxazolidinones and lipoglycopeptides[J]. J Clin Microbiol,2016,54(9):2225-2232.
|
| [8] |
BENSACI M,SAHM D.Surveillance of tedizolid activity and resistance:in vitro susceptibility of Gram-positive pathogens collected over 5 years from the United States and Europe[J]. Diagn Microbiol Infect Dis,2017,87(2):133-138.
|
| [9] |
BARBER K E,SMITH J R,RAUT A,et al.Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin,daptomycin or linezolid[J]. J Antimicrob Chemother,2016,71(1):152-155.
|
| [10] |
LI S,GUO Y,ZHAO C,et al.In vitro activities of tedizolid compared with other antibiotics against Gram-positive pathogens associated with hospital-acquired pneumonia,skin and soft tissue infection and bloodstream infection collected from 26 hospitals in China[J]. J Med Microbiol,2016,65(10):1215-1224.
|
| [11] |
RAJAN S.Skin and soft-tissue infections:classifying and treating a spectrum[J]. Cleve Clin J Med,2012,79(1):57-66.
|
| [12] |
SHORR A F,LODISE T P,COREY G R,et al.Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections[J]. Antimicrob Agents Chemother,2015,59(2):864-871.
|
| [13] |
MORAN G J,FANG E,COREY G R,et al.Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2):a randomised,double-blind,phase 3,non-inferiority trial[J]. Lancet Infect Dis,2014,14(8):696-705.
|
| [14] |
DAS D,TULKENS P M,MEHRA P,et al.Tedizolid phosphate for the management of acute bacterial skin and skin structure infections:safety summary[J]. Clin Infect Dis,2014,58(Suppl 1):S51-S57.
|
| [15] |
BURDETTE S D,TROTMAN R.Tedizolid:the first once-daily oxazolidinone class antibiotic[J]. Clin Infect Dis,2015,61(8):1315-1321.
|
| [16] |
WOODFORD N,LIVERMORE D M.Infections caused by Gram-positive bacteria:a review of the global challenge[J]. J Infect,2009,59(Suppl 1):S4-S16.
|
| [17] |
Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically[S]. M07-A10,CLSI,2015.
|
| [18] |
Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing[S]. M100-S26,CLSI,2016.
|
| [19] |
KEHRENBERG C,SCHWARZ S.Distribution of florfenicol resistance genes fexA and cfr among chloramphenicol-resistant Staphylococcus isolates[J]. Antimicrob Agents Chemother,2006,50(4): 1156-1163.
|
| [20] |
WANG Y,LV Y,CAI J,et al.A novel gene,optrA,that confers transferable resistance to oxazolidinones and phenicols and its presence in Enterococcus faecalis and Enterococcus faecium of human and animal origin[J]. J Antimicrob Chemother,2015,70(8):2182-2190.
|
| [21] |
BOURGEOIS-NICOLAOS N,MASSIAS L,COUSON B,et al.Dose dependence of emergence of resistance to linezolid in Enterococcus faecalis in vivo[J]. J Infect Dis,2007,195(10):1480-1488.
|
| [22] |
ZHANEL G G,LOVE R,ADAM H,et al.Tedizolid:a novel oxazolidinone with potent activity against multidrug-resistant Gram-positive pathogens[J]. Drugs,2015,75(3):253-270.
|
| [23] |
FERRÁNDEZ O,URBINA O,GRAU S. Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infections[J]. Drug Des Devel Ther,2016,11:65-82.
|
| [24] |
BAEK J Y,KANG C I,KIM S H,et al.In vitro activity of tedizolid phosphate against multidrug-resistant Streptococcus pneumoniae isolates from Asian countries[J]. Diagn Microbiol Infect Dis,2016,85(2):218-220.
|
| [25] |
BIEDENBACH D J,BOUCHILLON S K, JOHNSON B,et al.In vitro activity of tedizolid against Staphylococcus aureus and Streptococcus pneumoniae collected in 2013 and 2014 from sites in Latin American countries,Australia,New Zealand,and China[J]. Eur J Clin Microbiol Infect Dis,2016,35(12):1933-1939.
|
| [26] |
HE T,SHEN Y,SCHWARZ S,et al.Genetic environment of the transferable oxazolidinone/phenicol resistance gene optrA in Enterococcus faecalis isolates of human and animal origin[J]. J Antimicrob Chemother,2016,71(6):1466-1473.
|
| [27] |
CAI J,WANG Y,SCHWARZ S,et al. Enterococcal isolates carrying the novel oxazolidinone resistance gene optrA from hospitals in Zhejiang,Guangdong,and Henan,China,2010-2014[J]. Clin Microbiol Infect,2015,21(12):1095.e1-e4.
|
)
